

# Toward Standards for Machine Learning Research in Health Care and Policy



October 24, 2019

**Sherri Rose, Ph.D.**

Associate Professor

Department of Health Care Policy


Harvard Medical School

Co-Director

Health Policy Data Science Lab

[drsherrirose.org](http://drsherrirose.org)

 @sherrirose 





“ Learning two fields takes, surprisingly, twice as long as learning one. But it’s worth the investment because you get to solve real problems for the first time. ”

Barbara Engelhardt | Princeton



“ In both private enterprise and the public sector, research must be reflective of the society we’re serving. ”

Rediet Abebe | Harvard & Cornell



“ ...behind every data point there is a human story, there is a family, and there is suffering. ”

Nick Jewell | LSHTM & UC Berkeley

# DATA

# DATA



# Electronic Databases

The increasing availability of electronic health information offers a resource to health researchers

# Electronic Databases

The increasing availability of electronic health information offers a **resource to health researchers**

General usefulness of this type of data to answer targeted scientific research questions is an open question

# Electronic Databases

The increasing availability of electronic health information offers a **resource to health researchers**

General usefulness of this type of data to answer targeted scientific research questions is an open question

# Electronic Databases

The increasing availability of electronic health information offers a **resource to health researchers**

General usefulness of this type of data to answer targeted scientific research questions is an open question varies

# Electronic Databases

The increasing availability of electronic health information offers a **resource to health researchers**

General usefulness of this type of data to answer targeted scientific research questions is an open question varies

May need **novel statistical methods** that have desirable properties while remaining computationally feasible


## Electronic Databases: EHR $\neq$ EHR

The increasing availability of electronic health information offers a resource to health researchers

General usefulness of this type of data to answer targeted scientific research questions is an open question varies

May need **novel statistical methods** that have desirable properties while remaining computationally feasible

## BILLING CLAIMS



## CLINICAL RECORDS

### IMAGING



## REGISTRIES



## SURVEYS



## GOVERNMENT SOURCES



## WEARABLE & IMPLANTABLE TECH



## DIGITAL




## NEWS MEDIA




# GENERALIZABILITY







RANDOMIZED TRIAL





OBSERVATIONAL STUDY






TARGET POPULATION













Invited Commentary | Health Informatics

## Machine Learning for Prediction in Electronic Health Data

Sherri Rose, PhD






Invited Commentary | Health Informatics

## Machine Learning for Prediction in Electronic Health Data


Sherri Rose, PhD



“ The machine learning researchers who develop novel algorithms for prediction and the clinical teams interested in implementing them are frequently and unfortunately 2 nonintersecting groups. ”

# DATASET SHIFT

# Chronic Conditions




## Risk Adjustment for Health Plan Payment

Randall P. Ellis, Bruno Martins and Sherri Rose




# Number of Diagnoses Reported



# Variable Selection and Upcoding

Reduced set of 10 variables 92% as efficient




A Machine Learning Framework for  
Plan Payment Risk Adjustment

*Sherri Rose*



# Variable Selection and Upcoding

Reduced set of 10 variables 92% as efficient



“...results for the risk adjustment algorithms that considered a limited subset of variables...performed consistently worse across all benchmarks.”

## Sample Selection for Medicare Risk Adjustment Due to Systematically Missing Data

*Savannah L. Bergquist* , *Thomas G. McGuire*,  
*Timothy J. Layton* , and *Sherri Rose* 




## A Machine Learning Framework for Plan Payment Risk Adjustment

*Sherri Rose*



# Prediction Using the “Wrong” Data




**Matching and Imputation Methods for Risk Adjustment in the Health Insurance Marketplaces**

Sherri Rose   Julie Shi   Thomas G. McGuire  
Sharon-Lise T. Normand



# Prediction Using the “Wrong” Data



Sample Selection for Medicare Risk Adjustment Due to Systematically Missing Data

*Savannah L. Bergquist* , *Thomas G. McGuire*,  
*Timothy J. Layton* , and *Sherri Rose* 



**Matching and Imputation Methods for Risk Adjustment in the Health Insurance Marketplaces**

Sherri Rose   Julie Shi   Thomas G. McGuire  
Sharon-Lise T. Normand



# FAIRNESS

Who decides the research question?

Who is in the target population?

What do the data reflect?

How will the algorithm be assessed?

**Prediction**

**Clustering**


**Inference**

**Generalizability**

**Fairness**

# Black Patients Miss Out On Promising Cancer Drugs

A ProPublica analysis found that black people and Native Americans are under-represented in clinical trials of new drugs, even when the treatment is aimed at a type of cancer that disproportionately affects them.



**Note:** Drugs are labeled "Similar Risk" if black Americans are at least 80 percent as likely as white Americans to be diagnosed with the cancer treated.



## Perspective


# Machine Learning and Prediction in Medicine — Beyond the Peak of Inflated Expectations

Jonathan H. Chen, M.D., Ph.D., and Steven M. Asch, M.D., M.P.H.

Yet there are problems with real-world data sources. Whereas conventional approaches are largely based on data from cohorts that are carefully constructed to mitigate bias, emerging data sources are typically less structured, since they were designed to serve a different purpose (e.g., clinical care and billing). Issues ranging from patient self-selection to confounding by indication to inconsistent availability of outcome data can result in inadvertent bias, and even racial profiling, in machine predictions. Awareness of such challenges may keep the hype from outpacing the hope for how data analytics can improve medical decision making.

# Algorithmic Fairness

Common measures of fairness are based on the notion of **group fairness**, striving for similarity in predicted outcomes or errors for groups




# Global vs. Group Fit


**R<sup>2</sup>**      **MHSUD**  
**Net Compensation**

1. baseline formula	13.1%	-\$2,822
---------------------	-------	----------


# Global vs. Group Fit



# Global vs. Group Fit



# Global vs. Group Fit



# MORE ON METRICS

# How Do We Evaluate Classifiers?

## Area Under the Receiver Operating Characteristic Curve (AUC):

Summary metric of the predictive discrimination, specifically measuring the ranking performance for random discordant pairs

- ▶ Assessing prediction performance primarily using AUC can be misleading
- ▶ **Leaderboard AUC:** Despite many published warnings, machine learning competitions and articles often assign their leaderboard and winners solely on a single metric – often AUC for classification

# How Do We Evaluate Classifiers?

$$\text{True Positive Rate} = \frac{\text{True Positives}}{\text{True Positives} + \text{False Negatives}}$$

also known as:  
Sensitivity and Recall

$$\text{False Positive Rate} = \frac{\text{False Positives}}{\text{False Positives} + \text{True Negatives}}$$

also known as:  
1-Specificity

$$\text{Positive Predictive Value} = \frac{\text{True Positives}}{\text{True Positives} + \text{False Positives}}$$

also known as:  
Precision

$$\text{Accuracy} = \frac{\text{True Positives} + \text{True Negatives}}{n}$$

... and more, including **calibration**.

# Aortic Valves Study

$$\text{True Positive Rate} = \frac{\text{True Positives}}{\text{True Positives} + \text{False Negatives}}$$

also known as:  
Sensitivity and Recall

$$\text{False Positive Rate} = \frac{\text{False Positives}}{\text{False Positives} + \text{True Negatives}} = 0\%$$

also known as:  
1-Specificity

$$\text{Positive Predictive Value} = \frac{\text{True Positives}}{\text{True Positives} + \text{False Positives}}$$

also known as:  
Precision

$$\text{Accuracy} = \frac{\text{True Positives} + \text{True Negatives}}{n}$$

# Aortic Valves Study

$$\text{True Positive Rate} = \frac{\text{True Positives}}{\text{True Positives} + \text{False Negatives}}$$

also known as:  
Sensitivity and Recall

$$\text{False Positive Rate} = \frac{\text{False Positives}}{\text{False Positives} + \text{True Negatives}} = 0\%$$

also known as:  
1-Specificity

$$\text{Positive Predictive Value} = \frac{\text{True Positives}}{\text{True Positives} + \text{False Positives}} = 100\%$$

also known as:  
Precision

$$\text{Accuracy} = \frac{\text{True Positives} + \text{True Negatives}}{n}$$

# Aortic Valves Study

$$\text{True Positive Rate} = \frac{\text{True Positives}}{\text{True Positives} + \text{False Negatives}}$$

also known as:  
Sensitivity and Recall

$$\text{False Positive Rate} = \frac{\text{False Positives}}{\text{False Positives} + \text{True Negatives}} = 0\%$$

also known as:  
1-Specificity

$$\text{Positive Predictive Value} = \frac{\text{True Positives}}{\text{True Positives} + \text{False Positives}} = 100\%$$

also known as:  
Precision

$$\text{Accuracy} = \frac{\text{True Positives} + \text{True Negatives}}{n} = 98\%$$

# Aortic Valves Study

$$\text{True Positive Rate} = \frac{\text{True Positives}}{\text{True Positives} + \text{False Negatives}}$$

also known as:  
Sensitivity and Recall

$$\text{False Positive Rate} = \frac{\text{False Positives}}{\text{False Positives} + \text{True Negatives}} = 0\%$$

also known as:  
1-Specificity

$$\text{Positive Predictive Value} = \frac{\text{True Positives}}{\text{True Positives} + \text{False Positives}} = 100\%$$

also known as:  
Precision

$$\text{Accuracy} = \frac{\text{True Positives} + \text{True Negatives}}{n} = 98\%$$

$$\text{AUC} = 73\%$$

## Aortic Valves Study

$$\text{True Positive Rate} = \frac{\text{True Positives}}{\text{True Positives} + \text{False Negatives}} = 1\%$$

also known as:  
Sensitivity and Recall

$$\text{False Positive Rate} = \frac{\text{False Positives}}{\text{False Positives} + \text{True Negatives}} = 0\%$$

also known as:  
1-Specificity

$$\text{Positive Predictive Value} = \frac{\text{True Positives}}{\text{True Positives} + \text{False Positives}} = 100\%$$

also known as:

$$\text{Accuracy} = \frac{\text{True Positives} + \text{True Negatives}}{n} = 98\%$$

AUC = 73%

# HUMANS + MACHINES

# Predicting Unprofitability

## Profit-Maximizing Insurer:

- ▶ Design plan to attract profitable & deter unprofitable enrollees
- ▶ Cannot discriminate based on pre-existing conditions
- ▶ Raise/lower out of pocket costs of drugs for some conditions
- ▶ Distortions make it difficult for unprofitable groups to find acceptable coverage



\$\$

ibx.com

Demonstrate drug formulary identifies unprofitable enrollees

Computational health economics for identification of unprofitable health care enrollees

Sherri Rose, Savannah L. Bergquist, Timothy J. Layton



# Predicting Unprofitability

- ▶ Limit to ~10 non-zero variables
- ▶ Augment with therapeutic classes for HIV & multiple sclerosis drugs

```
39 # lasso screener that always retains classes for HIV and MS drugs
40 var.index <- c(which(colnames(newdat)=="tcls14"), which(colnames(newdat)=="tcls251"))
41
42 screen.glmnet10 <- function(Y, X, family, alpha = 1, minscreen = 2, nfolds = 10, nlambd = 100, fixed.var.index=var.index, ...) {
43   # .SL.require('glmnet')
44   if(is.matrix(X)) {
45     X <- model.matrix(~ -1 + ., X)
46   }
47   fitCV <- glmnet::cv.glmnet(x = X, y = Y, lambda = NULL, type.measure = 'deviance',
48                               nfolds = nfolds, family = family$family, alpha = alpha,
49                               nlambd = nlambd, pmax=10, parallel=T)
50   whichVariable <- (as.numeric(coef(fitCV$glmnet.fit, s = fitCV$lambda.min))[-1] != 0)
51   # the [-1] removes the intercept; taking the coefs from the fit w/ lambda that gives minimum cvm
52   if (sum(whichVariable) < minscreen) {
53     warning("fewer than minscreen variables passed the glmnet screen,
54            increased lambda to allow minscreen variables")
55     sumCoef <- apply(as.matrix(fitCV$glmnet.fit$beta), 2, function(x) sum((x != 0)))
56     newCut <- which.max(sumCoef) >= minscreen
57     whichVariable <- (as.matrix(fitCV$glmnet.fit$beta)[, newCut] != 0)
58   }
59   whichVariable[c(var.index)] <- TRUE
60   return(whichVariable)
61 }
```

sl-bergquist.github.io/unprofits

IN CLOSING



**Bryan Cantrill**

@bcantrill

How about a conference called "In Retrospect" in which presenters revisit talks they've given years prior -- and describe how their thinking has evolved since?

7:01 PM - 28 Jun 2018

---

1,036 Retweets 5,714 Likes



## Publish houses of brick, not mansions of straw

Papers need to include fewer claims and more proof to make the scientific literature more reliable, warns

**William G. Kaelin Jr.**

23 May 2017

*NATURE* | COLUMN: WORLD VIEW

“ ...goal of a paper seems to have shifted from validating specific conclusions to making the broadest possible assertions. ”

# Role of Tutorials

## Practice of Epidemiology

---

### Mortality Risk Score Prediction in an Elderly Population Using Machine Learning

Sherri Rose\*



## Practice of Epidemiology

---

### Targeted Maximum Likelihood Estimation for Causal Inference in Observational Studies

Megan S. Schuler and Sherri Rose\*



---

*International Journal of Epidemiology*, 2019, 1–7

doi: 10.1093/ije/dyz132

Education Corner

### Reflection on modern methods: when worlds collide—prediction, machine learning and causal inference

Tony Blakely,<sup>1</sup>\* John Lynch,<sup>2</sup> Koen Simons,<sup>1</sup> Rebecca Bentley<sup>1</sup> and Sherri Rose<sup>3</sup>

# Preprints, Data, and Code

arXiv.org



medRxiv



bioRxiv

# Does Your Algorithm Have a Social Impact Statement?

**Responsibility**

**Explainability**

**Accuracy**

**Auditability**

**Fairness**

- 1. Improvements to research infrastructure needed**
- 2. Types of training most important for this research**
- 3. Future research needs**

## **1. Improvements to research infrastructure needed**

Developing and maintaining software

## **2. Types of training most important for this research**

## **3. Future research needs**

# 1. Improvements to research infrastructure needed

Developing and maintaining software

# 2. Types of training most important for this research



“ Learning two fields takes, surprisingly, twice as long as learning one. But it’s worth the investment because you get to solve real problems for the first time. ”

Barbara Engelhardt | Princeton

# 3. Future research needs

# 1. Improvements to research infrastructure needed

Developing and maintaining software

# 2. Types of training most important for this research



“ Learning two fields takes, surprisingly, twice as long as learning one. But it’s worth the investment because you get to solve real problems for the first time. ”

Barbara Engelhardt | Princeton

# 3. Future research needs

Does Your Algorithm Have a Social Impact Statement?

Responsibility   Explainability  
Accuracy   Auditability  
Fairness

# 1. Improvements to research infrastructure needed

Developing and maintaining software

# 2. Types of training most important for this research



“ Learning two fields takes, surprisingly, twice as long as learning one. But it’s worth the investment because you get to solve real problems for the first time. ”

Barbara Engelhardt | Princeton

# 3. Future research needs

Does Your Algorithm Have a Social Impact Statement? Machine learning for causal inference in *Biostatistics*

Responsibility Explainability  
Accuracy Auditability  
Fairness

SHERRI ROSE

Department of Health Care Policy, Harvard Medical School

rose@hcp.med.harvard.edu

and

DIMITRIS RIZOPOULOS

Department of Biostatistics, Erasmus University Medical Center

# 1. Improvements to research infrastructure needed

Developing and maintaining software

# 2. Types of training most important for this research



“ Learning two fields takes, surprisingly, twice as long as learning one. But it’s worth the investment because you get to solve real problems for the first time. ”

Barbara Engelhardt | Princeton

# 3. Future research needs

Does Your Algorithm Have a Social Impact Statement? Machine learning for causal inference in *Biostatistics*

Responsibility Explainability  
Accuracy Auditability  
Fairness

SHERRI ROSE

Department of Health Care Policy, Harvard Medical School

rose@hcp.med.harvard.edu

and

DIMITRIS RIZOPOULOS

Department of Biostatistics, Erasmus University Medical Center

Standards and guidelines adopted by the community  
followed by buy-in from journals and grantors

# Acknowledgements



Sam Adhikari, PhD  
NYU



Austin Denteh, PhD  
Tulane




Savannah Bergquist, PhD  
Berkeley Haas




Akritee Shrestha, MS  
Wayfair



Maia Majumder, PhD  
Harvard



Alex McDowell  
Harvard



Anna Zink  
Harvard



Toyya Pujol  
Georgia Tech



Irina Degtiar  
Harvard



Christoph Kurz  
University of Munich

## Funding:

NIH Director's New Innovator Award (DP2-MD012722)

Laura and John Arnold Foundation

NIH R01-GM111339

